JP7900840B2 - 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用 - Google Patents

置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用

Info

Publication number
JP7900840B2
JP7900840B2 JP2024522243A JP2024522243A JP7900840B2 JP 7900840 B2 JP7900840 B2 JP 7900840B2 JP 2024522243 A JP2024522243 A JP 2024522243A JP 2024522243 A JP2024522243 A JP 2024522243A JP 7900840 B2 JP7900840 B2 JP 7900840B2
Authority
JP
Japan
Prior art keywords
quinoline
pyrazolo
alkyl
methoxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024522243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539633A5 (enExample
JP2024539633A (ja
Inventor
アバギャン，ルーベン
ミトキン，オレグ
ゼノノヴィチ パーチンスキー，ウラジスラフ
プシェチニコフ，アレクセイ
ヴァシリエヴィチ イヴァチチェンコ，アレクサンドル
サブチュク，ニコライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lomond Therapeutics Inc
Original Assignee
Lomond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lomond Therapeutics Inc filed Critical Lomond Therapeutics Inc
Publication of JP2024539633A publication Critical patent/JP2024539633A/ja
Publication of JP2024539633A5 publication Critical patent/JP2024539633A5/ja
Application granted granted Critical
Publication of JP7900840B2 publication Critical patent/JP7900840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024522243A 2021-10-15 2022-10-03 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用 Active JP7900840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256260P 2021-10-15 2021-10-15
US63/256,260 2021-10-15
PCT/US2022/045555 WO2023064133A1 (en) 2021-10-15 2022-10-03 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF

Publications (3)

Publication Number Publication Date
JP2024539633A JP2024539633A (ja) 2024-10-29
JP2024539633A5 JP2024539633A5 (enExample) 2025-06-23
JP7900840B2 true JP7900840B2 (ja) 2026-08-05

Family

ID=85988576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522243A Active JP7900840B2 (ja) 2021-10-15 2022-10-03 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用

Country Status (11)

Country Link
US (1) US20250011319A1 (enExample)
EP (1) EP4416146A4 (enExample)
JP (1) JP7900840B2 (enExample)
KR (1) KR20240093606A (enExample)
CN (1) CN118076605A (enExample)
AU (1) AU2022364646B2 (enExample)
CA (1) CA3233233A1 (enExample)
MX (1) MX2024004569A (enExample)
TW (2) TWI863003B (enExample)
WO (1) WO2023064133A1 (enExample)
ZA (1) ZA202406375B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用
WO2026080918A1 (en) * 2024-10-11 2026-04-16 Lomond Therapeutics, Inc. Synthesis of a tetrahydroisoquinolin-pyrazoloquinolin compound and pharmaceutically acceptable salts thereof
WO2026080917A1 (en) * 2024-10-11 2026-04-16 Lomond Therapeutics, Inc. Polymorphs and solid forms of a tetrahydroisoquinolinpyrazoloquinolin compound, and pharmaceutical compositions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
WO2021142252A1 (en) 2020-01-10 2021-07-15 Incyte Corporation Tricyclic compounds as inhibitors of kras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61919B1 (sr) * 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
MA55478A (fr) * 2019-03-26 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs bicycliques de hpk1
CN121270550A (zh) * 2020-04-16 2026-01-06 因赛特公司 稠合三环kras抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
WO2021142252A1 (en) 2020-01-10 2021-07-15 Incyte Corporation Tricyclic compounds as inhibitors of kras

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Database REGISTRY，2006年08月14日，RN 901229-71-8, RN 901229-60-5, RN 901229-53-6, RN 901229-38-7, RN 901229-32-1, RN 901229-27-4, RN 901229-21-8, RN 901229-15-0, RN 901229-09-2, RN 901030-92-0, RN 901030-90-8, RN 901030-86-2, RN 901030-84-0, RN 901030-82-8, RN 901030-80-6, RN 901030-78-2, RN 901030-76-0, RN 901030-72-6, Retrieved from STN international [online] ;retrieved on 04 Mar 2026

Also Published As

Publication number Publication date
US20250011319A1 (en) 2025-01-09
EP4416146A1 (en) 2024-08-21
CN118076605A (zh) 2024-05-24
MX2024004569A (es) 2024-04-30
JP2024539633A (ja) 2024-10-29
ZA202406375B (en) 2025-01-29
AU2022364646B2 (en) 2025-10-09
TWI863003B (zh) 2024-11-21
EP4416146A4 (en) 2025-11-05
WO2023064133A1 (en) 2023-04-20
KR20240093606A (ko) 2024-06-24
AU2022364646A1 (en) 2024-03-28
TW202442645A (zh) 2024-11-01
TW202317567A (zh) 2023-05-01
CA3233233A1 (en) 2023-04-20

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260716

R150 Certificate of patent or registration of utility model

Ref document number: 7900840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150